This systemic insulin excess, along with the potential mitogenic effects of insulin and some insulin analogues, may promote tumour growth, possibly via stimulation of the insulin-like growth factor 1 (IGF-1) axis, a pathway implicated in the pathogenesis of several cancers (77). Here, IGF1 is linked to cancer.